This is a news story, published by CNBC, that relates primarily to Anne Wojcicki news.
For more Anne Wojcicki news, you can click here:
more Anne Wojcicki newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
23andMe. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest exclusive genetic testing business news, pharmaceutical companies news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
23andMe CEO Anne WojcickiCNBC
•
85% Informative
23andMe faces a Nov. 4 deadline to keep its share price above $1 .
CEO Anne Wojcicki wants to take the company private.
The company faces a $312 million net loss in the 2023 fiscal year .
In October 2023 , hackers accessed the information of nearly 7 million customers.
VR Score
82
Informative language
78
Neutral language
92
Article tone
informal
Language
English
Language complexity
54
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Affiliate links
no affiliate links